Tanya Parish, PhD

Tanya Parish, PhD

Academic Title: Professor, Pediatrics

Research Title: Principal Investigator, Center for Global Infectious Disease Research, Seattle Children’s Research Institute

Research Center: Center for Global Infectious Disease Research

"As a trained microbiologist, I am motivated to use my scientific knowledge to make a difference in global health. My previous work on the basic biology of Mycobacterium tuberculosis formed an excellent foundation upon which to build a drug discovery team. Using knowledge of vulnerabilities in the bacterial pathogen, we can find tractable and novel drug targets. In addition, a grounding in bacterial physiology allows us to develop relevant screening platforms and to run a battery of experimental assays to select the best chemical series to work on in a drug discovery program. We work collaboratively with a large number of external partners, both industrial and academic, to advance new TB drugs. "

  • Complete List of Published Work in MyBibliography:


    Most recently, I was the Senior Vice President of Drug Discovery at the Infectious Disease Research Institute, where I established a research group focused on tuberculosis drug discovery group. Prior to that, I was Professor of Mycobacteriology at Barts and the London School of Medicine and Dentistry, with a research group focused on mycobacterial biology.

    BSc in Microbiology and Genetics, University College London, UK

    PhD, National Institute for Medical Research, London, UK

    Postdoctoral studies, London School of Hygiene & Tropical Medicine, UK

    • Related Pages

    • About My Work

      Our current research is focused in two main areas: (i) understanding the biology of the global pathogen Mycobacterium tuberculosis; and (ii) discovering and developing novel drugs for tuberculosis (TB) that are effective at curing drug sensitive and drug resistant tuberculosis.

  • Manuscripts in Refereed Journals

    • Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D, Johnson J, Korkegian A, Mullen S, Moure AL, Davis SH, Murugesan D, Mathieson M, Caldwell N, Engelhart CA, Schnappinger D, Epemolu O, Zuccotto F, Riley J, Scullion P, Stojanovski L, Massoudi L, Robertson GT, Lenaerts AJ, Freiberg G, Kempf DJ, Masquelin T, Hipskind PA, Odingo J, Read KD, Green SR, Wyatt PG, Parish T
      Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.
      33521468 ACS omega, 2021 Jan. 26 : 6(3)2284-2311 PMCID:PMC7841955
    • Thayer MB, Parish T
      Phenoxyalkylimidazoles with an oxadiazole moiety are subject to efflux in Mycobacterium tuberculosis.
      33481781 PloS one, 2021 : 16(1)e0239353 PMCID:PMC7822546
    • McNeil MB, O'Malley T, Dennison D, Shelton CD, Sunde B, Parish T
      Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
      33055263 mSphere, 2020 Oct. 14 : 5(5) PMCID:PMC7565900
    • de Oliveira JAM, Williams DE, Bonnett S, Johnson J, Parish T, Andersen RJ
      Diterpenoids isolated from the Samoan marine sponge Chelonaplysilla sp. inhibit Mycobacterium tuberculosis growth.
      32404991 The Journal of antibiotics, 2020 Aug. : 73(8)568-573
    • Punetha A, Ngo HX, Holbrook SYL, Green KD, Willby MJ, Bonnett SA, Krieger K, Dennis EK, Posey JE, Parish T, Tsodikov OV, Garneau-Tsodikova S
      Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from Mycobacterium tuberculosis.
      32421305 ACS chemical biology, 2020 June 19 : 15(6)1581-1594 PMCID:PMC7385556
    • Lefebvre C, Frigui W, Slama N, Lauzeral-Vizcaino F, Constant P, Lemassu A, Parish T, Eynard N, Daffé M, Brosch R, Quémard A
      Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis.
      32034201 Scientific reports, 2020 Feb. 7 : 10(1)2112 PMCID:PMC7005898
    • Flint L, Korkegian A, Parish T
      InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.
      33201882 PloS one, 2020 : 15(11)e0239354 PMCID:PMC7671525
    • Ferguson L, Wells G, Bhakta S, Johnson J, Guzman J, Parish T, Prentice RA, Brucoli F
      Integrated Target-Based and Phenotypic Screening Approaches for the Identification of Anti-Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA.
      31454170 ChemMedChem, 2019 Oct. 4 : 14(19)1735-1741 PMCID:PMC6800809
    • Odingo JO, Early JV, Smith J, Johnson J, Bailey MA, Files M, Guzman J, Ollinger J, Korkegian A, Kumar A, Ovechkina Y, Parish T
      8-Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis.
      30893501 Drug development research, 2019 Aug. : 80(5)566-572 PMCID:PMC6767403
    • Washburn A, Abdeen S, Ovechkina Y, Ray AM, Stevens M, Chitre S, Sivinski J, Park Y, Johnson J, Hoang QQ, Chapman E, Parish T, Johnson SM
      Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.
      31047750 Bioorganic & medicinal chemistry letters, 2019 July 1 : 29(13)1665-1672 PMCID:PMC6531345
    • Berube BJ, Russell D, Castro L, Choi SR, Narayanasamy P, Parish T
      Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors.
      30962346 Antimicrobial agents and chemotherapy, 2019 June : 63(6) PMCID:PMC6535543
    • Smith J, Wescott H, Early J, Mullen S, Guzman J, Odingo J, Lamar J, Parish T
      Anthranilic amide and imidazobenzothiadiazole compounds disrupt Mycobacterium tuberculosis membrane potential.
      31303991 MedChemComm, 2019 June 1 : 10(6)934-945 PMCID:PMC6596218
    • Crespo RA, Dang Q, Zhou NE, Guthrie LM, Snavely TC, Dong W, Loesch KA, Suzuki T, You L, Wang W, O'Malley T, Parish T, Olsen DB, Sacchettini JC
      Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.
      31002508 Journal of medicinal chemistry, 2019 May 9 : 62(9)4483-4499 PMCID:PMC6511943
    • Robertson GT, Ektnitphong VA, Scherman MS, McNeil MB, Dennison D, Korkegian A, Smith AJ, Halladay J, Carter DS, Xia Y, Zhou Y, Choi W, Berry PW, Mao W, Hernandez V, Alley MRK, Parish T, Lenaerts AJ
      Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
      30745397 Antimicrobial agents and chemotherapy, 2019 April : 63(4) PMCID:PMC6496157
    • Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, Gold B, Ochoada J, Wiernicki T, Masquelin T, Nathan C, Hipskind PA, Parish T
      Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.
      30501173 ACS infectious diseases, 2019 Feb. 8 : 5(2)272-280 PMCID:PMC6371205
    • McNeil MB, Chettiar S, Awasthi D, Parish T
      Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis.
      32974492 Access microbiology, 2019 : 1(1)e000006 PMCID:PMC7470358
    • Early JV, Mullen S, Parish T
      A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis.
      31589621 PloS one, 2019 : 14(10)e0222970 PMCID:PMC6779252
    • Dhiman RK, Pujari V, Kincaid JM, Ikeh MA, Parish T, Crick DC
      Characterization of MenA (isoprenyl diphosphate:1,4-dihydroxy-2-naphthoate isoprenyltransferase) from Mycobacterium tuberculosis.
      30978223 PloS one, 2019 : 14(4)e0214958 PMCID:PMC6461227
    • Ollinger J, Kumar A, Roberts DM, Bailey MA, Casey A, Parish T
      A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis.
      30650074 PloS one, 2019 : 14(1)e0205479 PMCID:PMC6334966
    • Melief E, Bonnett SA, Zuniga ES, Parish T
      Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase.
      30323042 Antimicrobial agents and chemotherapy, 2019 Jan. : 63(1) PMCID:PMC6325208
    • McGuffin S, Mullen S, Early J, Parish T.
      Development of a series of high-throughput screens to identify leads for nontuberculous mycobacteria drug design.
      Open Forum Infectious Diseases, 2019 - 2019 : Supplement(6); S485.
    • Carroll P, Muwanguzi-Karugaba J, Parish T
      Codon-optimized DsRed fluorescent protein for use in Mycobacterium tuberculosis.
      30285840 BMC research notes, 2018 Oct. 1 : 11(1)685 PMCID:PMC6167837
    • Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PG
      Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
      29944372 Journal of medicinal chemistry, 2018 Aug. 9 : 61(15)6592-6608 PMCID:PMC6089501
    • Singh SB, Odingo J, Bailey MA, Sunde B, Korkegian A, O'Malley T, Ovechkina Y, Ioerger TR, Sacchettini JC, Young K, Olsen DB, Parish T
      Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis.
      29954459 BMC research notes, 2018 June 28 : 11(1)416 PMCID:PMC6022709
    • Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M
      Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.
      30456352 Life science alliance, 2018 June : 1(3)e201800025 PMCID:PMC6238539
    • Martinez-Grau MA, Valcarcel ICG, Early JV, Gessner RK, de Melo CS, de la Nava EMM, Korkegian A, Ovechkina Y, Flint L, Gravelle A, Cramer JW, Desai PV, Street LJ, Odingo J, Masquelin T, Chibale K, Parish T
      Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis.
      29680666 Bioorganic & medicinal chemistry letters, 2018 June 1 : 28(10)1758-1764 PMCID:PMC5946847
    • O'Malley T, Alling T, Early JV, Wescott HA, Kumar A, Moraski GC, Miller MJ, Masquelin T, Hipskind PA, Parish T
      Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.
      29632008 Antimicrobial agents and chemotherapy, 2018 June : 62(6) PMCID:PMC5971599
    • Melief E, Kokoczka R, Files M, Bailey MA, Alling T, Li H, Ahn J, Misquith A, Korkegian A, Roberts D, Sacchettini J, Parish T
      Construction of an overexpression library for Mycobacterium tuberculosis.
      30197930 Biology methods & protocols, 2018 : 3(1)bpy009 PMCID:PMC6118195
    • Korkegian A, O'Malley T, Xia Y, Zhou Y, Carter DS, Sunde B, Flint L, Thompson D, Ioerger TR, Sacchettini J, Alley MRK, Parish T
      The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis.
      29523334 Tuberculosis (Edinburgh, Scotland), 2018 Jan. : 10896-98 PMCID:PMC5854369
    • Wescott HH, Zuniga ES, Bajpai A, Trujillo C, Ehrt S, Schnappinger D, Roberts DM, Parish T
      Identification of Enolase as the Target of 2-Aminothiazoles in Mycobacterium tuberculosis.
      30416491 Frontiers in microbiology, 2018 : 92542 PMCID:PMC6213970
    • Berube BJ, Castro L, Russell D, Ovechkina Y, Parish T
      Novel Screen to Assess Bactericidal Activity of Compounds Against Non-replicating Mycobacterium abscessus.
      30364170 Frontiers in microbiology, 2018 : 92417 PMCID:PMC6191478
    • Bonnett SA, Dennison D, Files M, Bajpai A, Parish T
      A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
      30332412 PloS one, 2018 : 13(10)e0198059 PMCID:PMC6192558
    • Njikan S, Manning AJ, Ovechkina Y, Awasthi D, Parish T
      High content, high-throughput screening for small molecule inducers of NF-κB translocation.
      29953522 PloS one, 2018 : 13(6)e0199966 PMCID:PMC6023200
    • Berube BJ, Parish T
      Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis.
      29061760 Antimicrobial agents and chemotherapy, 2018 Jan. : 62(1) PMCID:PMC5740367
    • Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O'Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchettini J, Masquelin T, Hipskind PA, Odingo J, Parish T
      Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.
      29035551 ACS infectious diseases, 2017 Dec. 8 : 3(12)898-916 PMCID:PMC5727484
    • McNeil MB, Dennison D, Shelton C, Flint L, Korkegian A, Parish T
      Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.
      29050761 Tuberculosis (Edinburgh, Scotland), 2017 Dec. : 107133-136 PMCID:PMC5679704
    • McNeil MB, Dennison DD, Shelton CD, Parish T
      In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.
      28760892 Antimicrobial agents and chemotherapy, 2017 Oct. : 61(10) PMCID:PMC5610523
    • Patel N, O'Malley T, Zhang YK, Xia Y, Sunde B, Flint L, Korkegian A, Ioerger TR, Sacchettini J, Alley MRK, Parish T
      A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosis In Vitro.
      28674058 Antimicrobial agents and chemotherapy, 2017 Sept. : 61(9) PMCID:PMC5571309
    • Manning AJ, Ovechkina Y, McGillivray A, Flint L, Roberts DM, Parish T
      A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.
      28366666 Methods (San Diego, Calif.), 2017 Aug. 15 : 1273-11
    • Zuniga ES, Korkegian A, Mullen S, Hembre EJ, Ornstein PL, Cortez G, Biswas K, Kumar N, Cramer J, Masquelin T, Hipskind PA, Odingo J, Parish T
      The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.
      28576632 Bioorganic & medicinal chemistry, 2017 Aug. 1 : 25(15)3922-3946 PMCID:PMC5513444
    • McNeil MB, Dennison D, Parish T
      Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis.
      28703701 Microbiology (Reading, England), 2017 July : 163(7)1065-1070
    • Howell Wescott HA, Roberts DM, Allebach CL, Kokoczka R, Parish T
      Imidazoles Induce Reactive Oxygen Species in Mycobacterium tuberculosis Which Is Not Associated with Cell Death.
      28180188 ACS omega, 2017 Jan. 31 : 2(1)41-51 PMCID:PMC5286457
    • Kokoczka R, Schuessler DL, Early JV, Parish T
      Mycobacterium tuberculosis Rv0560c is not essential for growth in vitro or in macrophages.
      28061949 Tuberculosis (Edinburgh, Scotland), 2017 Jan. : 1023-7 PMCID:PMC5225668
    • Bailey MA, Na H, Duthie MS, Gillis TP, Lahiri R, Parish T
      Nitazoxanide is active against Mycobacterium leprae.
      28850614 PloS one, 2017 : 12(8)e0184107 PMCID:PMC5574600
    • Bonnett SA, Ollinger J, Chandrasekera S, Florio S, O'Malley T, Files M, Jee JA, Ahn J, Casey A, Ovechkina Y, Roberts D, Korkegian A, Parish T
      A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase.
      27642770 ACS infectious diseases, 2016 Dec. 9 : 2(12)893-902 PMCID:PMC5215716
    • Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR
      Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.
      27503647 Antimicrobial agents and chemotherapy, 2016 Oct. : 60(10)6271-80 PMCID:PMC5038265
    • Degiacomi G, Personne Y, Mondésert G, Ge X, Mandava CS, Hartkoorn RC, Boldrin F, Goel P, Peisker K, Benjak A, Barrio MB, Ventura M, Brown AC, Leblanc V, Bauer A, Sanyal S, Cole ST, Lagrange S, Parish T, Manganelli R
      Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis.
      27553416 Tuberculosis (Edinburgh, Scotland), 2016 Sept. : 10095-101
    • Martínez-Guitián M, Vázquez-Ucha JC, Odingo J, Parish T, Poza M, Waite RD, Bou G, Wareham DW, Beceiro A
      Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii.
      27139471 Antimicrobial agents and chemotherapy, 2016 July : 60(7)4375-9 PMCID:PMC4914650
    • Early JV, Casey A, Martinez-Grau MA, Gonzalez Valcarcel IC, Vieth M, Ollinger J, Bailey MA, Alling T, Files M, Ovechkina Y, Parish T
      Oxadiazoles Have Butyrate-Specific Conditional Activity against Mycobacterium tuberculosis.
      27044545 Antimicrobial agents and chemotherapy, 2016 June : 60(6)3608-16 PMCID:PMC4879361
    • Kesicki EA, Bailey MA, Ovechkina Y, Early JV, Alling T, Bowman J, Zuniga ES, Dalai S, Kumar N, Masquelin T, Hipskind PA, Odingo JO, Parish T
      Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents.
      27171280 PloS one, 2016 : 11(5)e0155209 PMCID:PMC4865136
    • Chandrasekera NS, Alling T, Bailey MA, Files M, Early JV, Ollinger J, Ovechkina Y, Masquelin T, Desai PV, Cramer JW, Hipskind PA, Odingo JO, Parish T
      Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.
      26295286 Journal of medicinal chemistry, 2015 Sept. 24 : 58(18)7273-85
    • Russo F, Gising J, Ã…kerbladh L, Roos AK, Naworyta A, Mowbray SL, Sokolowski A, Henderson I, Alling T, Bailey MA, Files M, Parish T, Karlén A, Larhed M
      Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents.
      26246997 ChemistryOpen, 2015 June : 4(3)342-62 PMCID:PMC4522185
    • Mullowney MW, Hwang CH, Newsome AG, Wei X, Tanouye U, Wan B, Carlson S, Barranis NJ, hAinmhire E, Chen WL, Krishnamoorthy K, White J, Blair R, Lee H, Burdette JE, Rathod PK, Parish T, Cho S, Franzblau SG, Murphy BT
      Diaza-anthracene Antibiotics from a Freshwater-Derived Actinomycete with Selective Antibacterial Activity toward Mycobacterium tuberculosis.
      26594660 ACS infectious diseases, 2015 April 10 : 1(4)168-174 PMCID:PMC4648258
    • Dragset MS, Poce G, Alfonso S, Padilla-Benavides T, Ioerger TR, Kaneko T, Sacchettini JC, Biava M, Parish T, Argüello JM, Steigedal M, Rubin EJ
      A novel antimycobacterial compound acts as an intracellular iron chelator.
      25645825 Antimicrobial agents and chemotherapy, 2015 April : 59(4)2256-64 PMCID:PMC4356758
    • Schreuder LJ, Carroll P, Muwanguzi-Karugaba J, Kokoczka R, Brown AC, Parish T
      Mycobacterium tuberculosis H37Rv has a single nucleotide polymorphism in PhoR which affects cell wall hydrophobicity and gene expression.
      25635271 Microbiology (Reading, England), 2015 April : 161(Pt 4)765-773
    • Chandrasekera NS, Alling T, Bailey M, Korkegian A, Ahn J, Ovechkina Y, Odingo J, Parish T
      The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity.
      25881065 Journal of negative results in biomedicine, 2015 Feb. 13 : 144 PMCID:PMC4336482
    • Moraski GC, Miller PA, Bailey MA, Ollinger J, Parish T, Boshoff HI, Cho S, Anderson JR, Mulugeta S, Franzblau SG, Miller MJ
      Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.
      25984566 ACS infectious diseases, 2015 Feb. 13 : 1(2)85-90 PMCID:PMC4426345
    • Carroll P, Parish T
      Deletion of cyp125 Confers Increased Sensitivity to Azoles in Mycobacterium tuberculosis.
      26197389 PloS one, 2015 : 10(7)e0133129 PMCID:PMC4510303
    • Goude R, Roberts DM, Parish T
      Electroporation of mycobacteria.
      25779313 Methods in molecular biology (Clifton, N.J.), 2015 : 1285117-30
    • Brown AC, Kokoczka R, Parish T
      LytB1 and LytB2 of Mycobacterium tuberculosis Are Not Genetically Redundant.
      26309039 PloS one, 2015 : 10(8)e0135638 PMCID:PMC4550268
    • Korkegian A, Roberts DM, Blair R, Parish T
      Mutations in the essential arabinosyltransferase EmbC lead to alterations in Mycobacterium tuberculosis lipoarabinomannan.
      25352598 The Journal of biological chemistry, 2014 Dec. 19 : 289(51)35172-81 PMCID:PMC4271206
    • Odingo J, O'Malley T, Kesicki EA, Alling T, Bailey MA, Early J, Ollinger J, Dalai S, Kumar N, Singh RV, Hipskind PA, Cramer JW, Ioerger T, Sacchettini J, Vickers R, Parish T
      Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.
      25456390 Bioorganic & medicinal chemistry, 2014 Dec. 15 : 22(24)6965-79
    • Carroll P, Muwanguzi-Karugaba J, Melief E, Files M, Parish T
      Identification of the translational start site of codon-optimized mCherry in Mycobacterium tuberculosis.
      24934902 BMC research notes, 2014 June 17 : 7366 PMCID:PMC4091752
    • Ekins S, Casey AC, Roberts D, Parish T, Bunin BA
      Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.
      24440548 Tuberculosis (Edinburgh, Scotland), 2014 March : 94(2)162-9 PMCID:PMC4394018
    • Chandrasekera NS, Bailey MA, Files M, Alling T, Florio SK, Ollinger J, Odingo JO, Parish T
      Synthesis and anti-tubercular activity of 3-substituted benzo[b]thiophene-1,1-dioxides.
      25320680 PeerJ, 2014 : 2e612 PMCID:PMC4193402
    • Personne Y, Parish T
      Mycobacterium tuberculosis possesses an unusual tmRNA rescue system.
      24145139 Tuberculosis (Edinburgh, Scotland), 2014 Jan. : 94(1)34-42
    • Schreuder LJ, Parish T
      Mycobacterium tuberculosis DosR is required for activity of the PmbtB and PmbtI promoters under hypoxia.
      25211224 PloS one, 2014 : 9(9)e107283 PMCID:PMC4161423
    • Karkare S, Brown AC, Parish T, Maxwell A
      Identification of the likely translational start of Mycobacterium tuberculosis GyrB.
      23856181 BMC research notes, 2013 July 15 : 6274 PMCID:PMC3724585
    • Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey M, Alling T, Ollinger J, Parish T, Miller MJ
      Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.
      23930153 ACS medicinal chemistry letters, 2013 July 11 : 4(7)675-679 PMCID:PMC3733398
    • Kumar D, Raj KK, Bailey M, Alling T, Parish T, Rawat DS
      Antimycobacterial activity evaluation, time-kill kinetic and 3D-QSAR study of C-(3-aminomethyl-cyclohexyl)-methylamine derivatives.
      23357633 Bioorganic & medicinal chemistry letters, 2013 March 1 : 23(5)1365-9
    • Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE 3rd, Sherman DR, Parish T, Sacchettini JC
      Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis.
      24086479 PloS one, 2013 : 8(9)e75245 PMCID:PMC3781026
    • Kumar A, Casey A, Odingo J, Kesicki EA, Abrahams G, Vieth M, Masquelin T, Mizrahi V, Hipskind PA, Sherman DR, Parish T
      A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis.
      24244263 PloS one, 2013 : 8(11)e72786 PMCID:PMC3820577
    • Personne Y, Brown AC, Schuessler DL, Parish T
      Mycobacterium tuberculosis ClpP proteases are co-transcribed but exhibit different substrate specificities.
      23560081 PloS one, 2013 : 8(4)e60228 PMCID:PMC3613350
    • Tan S, Sukumar N, Abramovitch RB, Parish T, Russell DG
      Mycobacterium tuberculosis responds to chloride and pH as synergistic cues to the immune status of its host cell.
      23592993 PLoS pathogens, 2013 : 9(4)e1003282 PMCID:PMC3616970
    • Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, Alling T, Miller MJ, Parish T
      A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.
      23593234 PloS one, 2013 : 8(4)e60531 PMCID:PMC3617142
    • James JN, Hasan ZU, Ioerger TR, Brown AC, Personne Y, Carroll P, Ikeh M, Tilston-Lunel NL, Palavecino C, Sacchettini JC, Parish T
      Deletion of SenX3-RegX3, a key two-component regulatory system of Mycobacterium smegmatis, results in growth defects under phosphate-limiting conditions.
      22956756 Microbiology (Reading, England), 2012 Nov. : 158(Pt 11)2724-2731
    • Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N, Robertson BD, Wiles S, Ward TH, Parish T, Ripoll J, Bancroft GJ, Schaible UE
      A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging.
      22635525 The Journal of antimicrobial chemotherapy, 2012 Aug. : 67(8)1948-60 PMCID:PMC3394442
    • Ollinger J, O'Malley T, Ahn J, Odingo J, Parish T
      Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions.
      22427625 Journal of bacteriology, 2012 May : 194(10)2614-9 PMCID:PMC3347204
    • Schuessler DL, Parish T
      The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis.
      22485172 PloS one, 2012 : 7(4)e34471 PMCID:PMC3317779
    • Pecsi I, Hirmondo R, Brown AC, Lopata A, Parish T, Vertessy BG, Tóth J
      The dUTPase enzyme is essential in Mycobacterium smegmatis.
      22655049 PloS one, 2012 : 7(5)e37461 PMCID:PMC3360063
    • Carroll P, Waddell SJ, Butcher PD, Parish T
      Methionine sulfoximine resistance in Mycobacterium tuberculosis is due to a single nucleotide deletion resulting in increased expression of the major glutamine synthetase, GlnA1.
      21875360 Microbial drug resistance (Larchmont, N.Y.), 2011 Sept. : 17(3)351-5 PMCID:PMC3161625
    • Carroll P, Faray-Kele MC, Parish T
      Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach.
      21642404 Applied and environmental microbiology, 2011 July : 77(14)5040-3 PMCID:PMC3147394
    • Davey MS, Lin CY, Roberts GW, Heuston S, Brown AC, Chess JA, Toleman MA, Gahan CG, Hill C, Parish T, Williams JD, Davies SJ, Johnson DW, Topley N, Moser B, Eberl M
      Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection.
      21589907 PLoS pathogens, 2011 May : 7(5)e1002040 PMCID:PMC3093373
    • Muttucumaru DG, Smith DA, McMinn EJ, Reese V, Coler RN, Parish T
      Mycobacterium tuberculosis Rv0198c, a putative matrix metalloprotease is involved in pathogenicity.
      21216669 Tuberculosis (Edinburgh, Scotland), 2011 March : 91(2)111-6
    • Driscoll MD, McLean KJ, Cheesman MR, Jowitt TA, Howard M, Carroll P, Parish T, Munro AW
      Expression and characterization of Mycobacterium tuberculosis CYP144: common themes and lessons learned in the M. tuberculosis P450 enzyme family.
      20621636 Biochimica et biophysica acta, 2011 Jan. : 1814(1)76-87
    • Roberts G, Vadrevu IS, Madiraju MV, Parish T
      Control of CydB and GltA1 expression by the SenX3 RegX3 two component regulatory system of Mycobacterium tuberculosis.
      21698211 PloS one, 2011 : 6(6)e21090 PMCID:PMC3116866
    • Sacco E, Slama N, Bäckbro K, Parish T, Laval F, Daffé M, Eynard N, Quémard A
      Revisiting the assignment of Rv0241c to fatty acid synthase type II of Mycobacterium tuberculosis.
      20511508 Journal of bacteriology, 2010 Aug. : 192(15)4037-44 PMCID:PMC2916384
    • Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR Jr, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC
      Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories.
      20472797 Journal of bacteriology, 2010 July : 192(14)3645-53 PMCID:PMC2897344
    • Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S
      Optimisation of bioluminescent reporters for use with mycobacteria.
      20520722 PloS one, 2010 May 24 : 5(5)e10777 PMCID:PMC2875389
    • Brown AC, Eberl M, Crick DC, Jomaa H, Parish T
      The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs.
      20172995 Journal of bacteriology, 2010 May : 192(9)2424-33 PMCID:PMC2863480
    • Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T
      Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters.
      20352111 PloS one, 2010 March 23 : 5(3)e9823 PMCID:PMC2843721
    • Movahedzadeh F, Wheeler PR, Dinadayala P, Av-Gay Y, Parish T, Daffé M, Stoker NG
      Inositol monophosphate phosphatase genes of Mycobacterium tuberculosis.
      20167072 BMC microbiology, 2010 Feb. 18 : 1050 PMCID:PMC2834668
    • Eoh H, Narayanasamy P, Brown AC, Parish T, Brennan PJ, Crick DC
      Expression and characterization of soluble 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase from bacterial pathogens.
      20064433 Chemistry & biology, 2009 Dec. 24 : 16(12)1230-9 PMCID:PMC4020808
    • Goude R, Amin AG, Chatterjee D, Parish T
      The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis.
      19596878 Antimicrobial agents and chemotherapy, 2009 Oct. : 53(10)4138-46 PMCID:PMC2764220
    • McLean KJ, Carroll P, Lewis DG, Dunford AJ, Seward HE, Neeli R, Cheesman MR, Marsollier L, Douglas P, Smith WE, Rosenkrands I, Cole ST, Leys D, Parish T, Munro AW
      Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.
      18818197 The Journal of biological chemistry, 2008 Nov. 28 : 283(48)33406-16 PMCID:PMC2662266
    • Covarrubias AS, Högbom M, Bergfors T, Carroll P, Mannerstedt K, Oscarson S, Parish T, Jones TA, Mowbray SL
      Structural, biochemical, and in vivo investigations of the threonine synthase from Mycobacterium tuberculosis.
      18621388 Journal of molecular biology, 2008 Sept. 5 : 381(3)622-33
    • Movahedzadeh F, Williams A, Clark S, Hatch G, Smith D, ten Bokum A, Parish T, Bacon J, Stoker N
      Construction of a severely attenuated mutant of Mycobacterium tuberculosis for reducing risk to laboratory workers.
      18457997 Tuberculosis (Edinburgh, Scotland), 2008 Sept. : 88(5)375-81
    • Carroll P, Pashley CA, Parish T
      Functional analysis of GlnE, an essential adenylyl transferase in Mycobacterium tuberculosis.
      18469098 Journal of bacteriology, 2008 July : 190(14)4894-902 PMCID:PMC2446997
    • Goude R, Parish T
      The genetics of cell wall biosynthesis in Mycobacterium tuberculosis.
      18505396 Future microbiology, 2008 June : 3(3)299-313
    • Goude R, Amin AG, Chatterjee D, Parish T
      The critical role of embC in Mycobacterium tuberculosis.
      18424526 Journal of bacteriology, 2008 June : 190(12)4335-41 PMCID:PMC2446762
    • Brown AC, Parish T
      Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.
      18489786 BMC microbiology, 2008 May 20 : 878 PMCID:PMC2409342
    • Schneider CZ, Parish T, Basso LA, Santos DS
      The two chorismate mutases from both Mycobacterium tuberculosis and Mycobacterium smegmatis: biochemical analysis and limited regulation of promoter activity by aromatic amino acids.
      17965159 Journal of bacteriology, 2008 Jan. : 190(1)122-34 PMCID:PMC2223748
    • Amin AG, Goude R, Shi L, Zhang J, Chatterjee D, Parish T
      EmbA is an essential arabinosyltransferase in Mycobacterium tuberculosis.
      18174142 Microbiology (Reading, England), 2008 Jan. : 154(Pt 1)240-248 PMCID:PMC2885622
    • Eoh H, Brown AC, Buetow L, Hunter WN, Parish T, Kaur D, Brennan PJ, Crick DC
      Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development.
      17921290 Journal of bacteriology, 2007 Dec. : 189(24)8922-7 PMCID:PMC2168624
    • Buetow L, Brown AC, Parish T, Hunter WN
      The structure of Mycobacteria 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery.
      17956607 BMC structural biology, 2007 Oct. 23 : 768 PMCID:PMC2151065
    • Sacco E, Covarrubias AS, O'Hare HM, Carroll P, Eynard N, Jones TA, Parish T, Daffé M, Bäckbro K, Quémard A
      The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis.
      17804795 Proceedings of the National Academy of Sciences of the United States of America, 2007 Sept. 11 : 104(37)14628-33 PMCID:PMC1976197
    • Carroll P, Brown AC, Hartridge AR, Parish T
      Expression of Mycobacterium tuberculosis Rv1991c using an arabinose-inducible promoter demonstrates its role as a toxin.
      17623030 FEMS microbiology letters, 2007 Sept. : 274(1)73-82
    • Robertson D, Carroll P, Parish T
      Rapid recombination screening to test gene essentiality demonstrates that pyrH is essential in Mycobacterium tuberculosis.
      17719852 Tuberculosis (Edinburgh, Scotland), 2007 Sept. : 87(5)450-8
    • Read R, Pashley CA, Smith D, Parish T
      The role of GlnD in ammonia assimilation in Mycobacterium tuberculosis.
      17303474 Tuberculosis (Edinburgh, Scotland), 2007 July : 87(4)384-90 PMCID:PMC1913930
    • Parish T, Roberts G, Laval F, Schaeffer M, Daffé M, Duncan K
      Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG.
      17337570 Journal of bacteriology, 2007 May : 189(10)3721-8 PMCID:PMC1913321
    • Pashley CA, Brown AC, Robertson D, Parish T
      Identification of the Mycobacterium tuberculosis GlnE promoter and its response to nitrogen availability.
      16946267 Microbiology (Reading, England), 2006 Sept. : 152(Pt 9)2727-2734
    • Brown AC, Parish T
      Instability of the acetamide-inducible expression vector pJAM2 in Mycobacterium tuberculosis.
      16125237 Plasmid, 2006 Jan. : 55(1)81-6
    • Carroll P, Muttucumaru DG, Parish T
      Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis.
      15933004 Applied and environmental microbiology, 2005 June : 71(6)3077-84 PMCID:PMC1151860
    • Parish T, Schaeffer M, Roberts G, Duncan K
      HemZ is essential for heme biosynthesis in Mycobacterium tuberculosis.
      15850757 Tuberculosis (Edinburgh, Scotland), 2005 May : 85(3)197-204
    • Wheeler PR, Coldham NG, Keating L, Gordon SV, Wooff EE, Parish T, Hewinson RG
      Functional demonstration of reverse transsulfuration in the Mycobacterium tuberculosis complex reveals that methionine is the preferred sulfur source for pathogenic Mycobacteria.
      15576367 The Journal of biological chemistry, 2005 March 4 : 280(9)8069-78
    • Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, Huygen K, Ottenhoff TH, Franken KL, Andersen P, Doherty TM, Kaufmann SH, Grode L, Seiler P, Martin C, Gicquel B, Cole ST, Brodin P, Pym AS, Dalemans W, Cohen J, Lobet Y, Goonetilleke N, McShane H, Hill A, Parish T, Smith D, Stoker NG, Lowrie DB, Källenius G, Svenson S, Pawlowski A, Blake K, Marsh PD
      Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
      15687025 Tuberculosis (Edinburgh, Scotland), 2005 Jan. : 85(1-2)29-38
    • Bhakta S, Besra GS, Upton AM, Parish T, Sholto-Douglas-Vernon C, Gibson KJ, Knutton S, Gordon S, DaSilva RP, Anderton MC, Sim E
      Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target.
      15117974 The Journal of experimental medicine, 2004 May 3 : 199(9)1191-9 PMCID:PMC2211905
    • Muttucumaru DG, Roberts G, Hinds J, Stabler RA, Parish T
      Gene expression profile of Mycobacterium tuberculosis in a non-replicating state.
      15207493 Tuberculosis (Edinburgh, Scotland), 2004 : 84(3-4)239-46
    • Kendall SL, Movahedzadeh F, Rison SC, Wernisch L, Parish T, Duncan K, Betts JC, Stoker NG
      The Mycobacterium tuberculosis dosRS two-component system is induced by multiple stresses.
      15207494 Tuberculosis (Edinburgh, Scotland), 2004 : 84(3-4)247-55
    • Pashley CA, Parish T
      Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis.
      14680701 FEMS microbiology letters, 2003 Dec. 12 : 229(2)211-5
    • Parish T
      Starvation survival response of Mycobacterium tuberculosis.
      14594845 Journal of bacteriology, 2003 Nov. : 185(22)6702-6 PMCID:PMC262115
    • Parish T, Smith DA, Roberts G, Betts J, Stoker NG
      The senX3-regX3 two-component regulatory system of Mycobacterium tuberculosis is required for virulence.
      12777483 Microbiology (Reading, England), 2003 June : 149(Pt 6)1423-1435
    • Roberts G, Muttucumaru DG, Parish T
      Control of the acetamidase gene of Mycobacterium smegmatis by multiple regulators.
      12694921 FEMS microbiology letters, 2003 April 11 : 221(1)131-6
    • Parish T, Smith DA, Kendall S, Casali N, Bancroft GJ, Stoker NG
      Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis.
      12595424 Infection and immunity, 2003 March : 71(3)1134-40 PMCID:PMC148821
    • Wernisch L, Kendall SL, Soneji S, Wietzorrek A, Parish T, Hinds J, Butcher PD, Stoker NG
      Analysis of whole-genome microarray replicates using mixed models.
      12499293 Bioinformatics (Oxford, England), 2003 Jan. : 19(1)53-61
    • Pashley CA, Parish T, McAdam RA, Duncan K, Stoker NG
      Gene replacement in mycobacteria by using incompatible plasmids.
      12514036 Applied and environmental microbiology, 2003 Jan. : 69(1)517-23 PMCID:PMC152386
    • Greendyke R, Rajagopalan M, Parish T, Madiraju MVVS
      Conditional expression of Mycobacterium smegmatis dnaA, an essential DNA replication gene.
      12480893 Microbiology (Reading, England), 2002 Dec. : 148(Pt 12)3887-3900
    • Parish T, Stoker NG
      The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis.
      12368440 Microbiology (Reading, England), 2002 Oct. : 148(Pt 10)3069-3077
    • Dziadek J, Rajagopalan M, Parish T, Kurepina N, Greendyke R, Kreiswirth BN, Madiraju MV
      Mutations in the CCGTTCACA DnaA box of Mycobacterium tuberculosis oriC that abolish replication of oriC plasmids are tolerated on the chromosome.
      12081955 Journal of bacteriology, 2002 July : 184(14)3848-55 PMCID:PMC135179
    • Smith DA, Parish T, Stoker NG, Bancroft GJ
      Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates.
      11160012 Infection and immunity, 2001 Feb. : 69(2)1142-50 PMCID:PMC97996
    • Parish T, Lewis J, Stoker NG
      Use of the mycobacteriophage L5 excisionase in Mycobacterium tuberculosis to demonstrate gene essentiality.
      11800587 Tuberculosis (Edinburgh, Scotland), 2001 : 81(5-6)359-64
    • Gordhan BG, Parish T
      Gene Replacement using Pretreated DNA.
      21341070 Methods in molecular medicine, 2001 : 5477-92
    • Parish T, Turner J, Stoker NG
      amiA is a negative regulator of acetamidase expression in Mycobacterium smegmatis.
      11570974 BMC microbiology, 2001 : 119 PMCID:PMC56589
    • Parish T, Stoker NG
      glnE is an essential gene in Mycobacterium tuberculosis.
      11004169 Journal of bacteriology, 2000 Oct. : 182(20)5715-20 PMCID:PMC94692
    • Parish T, Stoker NG
      Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement.
      10931901 Microbiology (Reading, England), 2000 Aug. : 146 ( Pt 81969-1975
    • Parish T, Gordhan BG, McAdam RA, Duncan K, Mizrahi V, Stoker NG
      Production of mutants in amino acid biosynthesis genes of Mycobacterium tuberculosis by homologous recombination.
      10627047 Microbiology (Reading, England), 1999 Dec. : 145 ( Pt 13497-3503
    • Hinds J, Mahenthiralingam E, Kempsell KE, Duncan K, Stokes RW, Parish T, Stoker NG
      Enhanced gene replacement in mycobacteria.
      10217485 Microbiology (Reading, England), 1999 March : 145 ( Pt 3519-527
    • Triccas JA, Parish T, Britton WJ, Gicquel B
      An inducible expression system permitting the efficient purification of a recombinant antigen from Mycobacterium smegmatis.
      9809415 FEMS microbiology letters, 1998 Oct. 15 : 167(2)151-6
    • McNerney R, Wilson SM, Sidhu AM, Harley VS, al Suwaidi Z, Nye PM, Parish T, Stoker NG
      Inactivation of mycobacteriophage D29 using ferrous ammonium sulphate as a tool for the detection of viable Mycobacterium smegmatis and M. tuberculosis.
      9766200 Research in microbiology, 1998 July : 149(7)487-95
    • Wren BW, Stabler RA, Das SS, Butcher PD, Mangan JA, Clarke JD, Casali N, Parish T, Stoker NG
      Characterization of a haemolysin from Mycobacterium tuberculosis with homology to a virulence factor of Serpulina hyodysenteriae.
      9611795 Microbiology (Reading, England), 1998 May : 144 ( Pt 51205-11
    • Parish T, Liu J, Nikaido H, Stoker NG
      A Mycobacterium smegmatis mutant with a defective inositol monophosphate phosphatase gene homolog has altered cell envelope permeability.
      9401044 Journal of bacteriology, 1997 Dec. : 179(24)7827-33 PMCID:PMC179748
    • Parish T, Stoker NG
      Development and use of a conditional antisense mutagenesis system in mycobacteria.
      9297833 FEMS microbiology letters, 1997 Sept. 1 : 154(1)151-7
    • Parish T, Mahenthiralingam E, Draper P, Davis EO, Colston MJ
      Regulation of the inducible acetamidase gene of Mycobacterium smegmatis.
      9245815 Microbiology (Reading, England), 1997 July : 143 ( Pt 72267-76
    • Gordon S, Parish T, Roberts IS, Andrew PW
      The application of luciferase as a reporter of environmental regulation of gene expression in mycobacteria.
      7765445 Letters in applied microbiology, 1994 Nov. : 19(5)336-40

    Other Publications

    • Morbidoni HR, de la Iglesia AI, Figueroa V, Di Capua C, Ioerger TR, Parish T
      Mutations in the anti-sigma H factor RshA confer resistance to econazole and clotrimazole in Mycobacterium smegmatis.
      32974504 Access microbiology, 2019 : 1(10)e000070 PMCID:PMC7491931


Research Description

My research team is comprised of both biologists and chemists focused on the global infectious disease tuberculosis. We work in two main areas.

First, we are working on discovering new drugs for tuberculosis. TB is the leading cause of death from an infectious disease, with about 1.5 million deaths every year. The current treatment takes more than 6 months and involves multiple drugs. Our work aims to find new drug candidates that can be combined into a novel drug treatment regimen, with the aim of reducing the overall time of treatment. New drugs should also be able to treat drug resistant TB, which is becoming a major problem.

Our research on the more basic science side is focused on understanding how antibiotics function. We focus on what leads to bacterial death when exposed to antibiotics. We also work on the mechanisms of antibiotic resistance. I am especially interested in cell wall biosynthesis and aerobic respiration, as well as other essential cellular processes and gene regulation.